Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,037 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Activity against human immunodeficiency virus type 1, intracellular metabolism, and effects on human DNA polymerases of 4'-ethynyl-2-fluoro-2'-deoxyadenosine.
Nakata H, Amano M, Koh Y, Kodama E, Yang G, Bailey CM, Kohgo S, Hayakawa H, Matsuoka M, Anderson KS, Cheng YC, Mitsuya H. Nakata H, et al. Among authors: amano m. Antimicrob Agents Chemother. 2007 Aug;51(8):2701-8. doi: 10.1128/AAC.00277-07. Epub 2007 Jun 4. Antimicrob Agents Chemother. 2007. PMID: 17548498 Free PMC article.
GRL-02031, a novel nonpeptidic protease inhibitor (PI) containing a stereochemically defined fused cyclopentanyltetrahydrofuran potent against multi-PI-resistant human immunodeficiency virus type 1 in vitro.
Koh Y, Das D, Leschenko S, Nakata H, Ogata-Aoki H, Amano M, Nakayama M, Ghosh AK, Mitsuya H. Koh Y, et al. Among authors: amano m. Antimicrob Agents Chemother. 2009 Mar;53(3):997-1006. doi: 10.1128/AAC.00689-08. Epub 2008 Oct 27. Antimicrob Agents Chemother. 2009. PMID: 18955518 Free PMC article.
Design, synthesis, protein-ligand X-ray structure, and biological evaluation of a series of novel macrocyclic human immunodeficiency virus-1 protease inhibitors to combat drug resistance.
Ghosh AK, Kulkarni S, Anderson DD, Hong L, Baldridge A, Wang YF, Chumanevich AA, Kovalevsky AY, Tojo Y, Amano M, Koh Y, Tang J, Weber IT, Mitsuya H. Ghosh AK, et al. Among authors: amano m. J Med Chem. 2009 Dec 10;52(23):7689-705. doi: 10.1021/jm900695w. J Med Chem. 2009. PMID: 19746963 Free PMC article.
Novel protease inhibitors (PIs) containing macrocyclic components and 3(R),3a(S),6a(R)-bis-tetrahydrofuranylurethane that are potent against multi-PI-resistant HIV-1 variants in vitro.
Tojo Y, Koh Y, Amano M, Aoki M, Das D, Kulkarni S, Anderson DD, Ghosh AK, Mitsuya H. Tojo Y, et al. Among authors: amano m. Antimicrob Agents Chemother. 2010 Aug;54(8):3460-70. doi: 10.1128/AAC.01766-09. Epub 2010 May 3. Antimicrob Agents Chemother. 2010. PMID: 20439612 Free PMC article.
In vitro selection of highly darunavir-resistant and replication-competent HIV-1 variants by using a mixture of clinical HIV-1 isolates resistant to multiple conventional protease inhibitors.
Koh Y, Amano M, Towata T, Danish M, Leshchenko-Yashchuk S, Das D, Nakayama M, Tojo Y, Ghosh AK, Mitsuya H. Koh Y, et al. Among authors: amano m. J Virol. 2010 Nov;84(22):11961-9. doi: 10.1128/JVI.00967-10. Epub 2010 Sep 1. J Virol. 2010. PMID: 20810732 Free PMC article.
1,037 results